Novo becomes second ever European firm to breach $500bn market value

Novo Nordisk shares have gained 60 per cent in the past year, fuelled by surging demand for Ozempic and Wegovy

Novo Nordisk: the company’s earnings sparked fresh optimism as the drugmaker said revenue could grow by as much as 26 per cent this year and operating profit by up to 29 per cent at constant exchange rates. Picture: Getty